sparc.life

Investors

Announcements & Disclosures

Quarterly Announcements & Disclosures

Independent Directors Familiarisation Program during the year 2019-20
Notice of Board Meeting on 2nd June 2020
Related Party Disclosures for half year ended on 31st March 2020

Newspaper Advertisement of 15th AGM through VC/OAVM
Notice for the 15th Annual General Meeting
Notice of Board Meeting on 4th August 2020
Related Party Disclosures for half year ended on 30th September 2020

Notice of Board Meeting on 9th November 2020
Proceedings of 15th Annual General Meeting
Voting Results of 15th Annual General Meeting
Transcript of the 15th Annual General Meeting

Notice of Board Meeting on 8th February 2021

Quarterly Announcements & Disclosures

Notice of Board Meeting on 7th May 2019
Detail of Independent Directors Familiarisation Program 2018-19
Related Party Disclosures for half year ended on 31st March 2019.
Notice for the 14th Annual General Meeting

Notice of Board Meeting on 29th July 2019
Proceedings of 14th Annual General Meeting
Voting Results of 14th Annual General Meeting
Notice of Board Meeting on 4th November 2019
Related Party Disclosures for half year ended on 30th September 2019
Update on Taclantis®
Investor Presentation – Update on R&D Pipeline
Press Release – Audio Playback for Update on R&D Pipeline

Notice of Board Meeting on 31st January 2020
SPARC Receives Orphan Drug Designation from the USFDA for Phenobarbital for the Treatment of Patients with Neonatal Seizures

Resignation by Mr. Mark Simon as Independent Director of the Company
Update on TACLANTIS™ (Paclitaxel Injection Concentrate for Suspension) NDA

Quarterly Announcements & Disclosures

Details of Independent Directors familiarisation Program - 2017-18
Notice of Board Meeting on 8th May 2018
Notice for the 13th Annual General Meeting

Notice of Board Meeting on 30th July 2018
Revised Articles of Association proposed for shareholders approval at 13th Annual General Meeting
Proceedings of 13th Annual General Meeting
Voting Results of 13th Annual General Meeting
Allotment of 50,50,505 equity shares on conversion of Warrants

Notice of Board Meeting on 29th October 2018
Inter-se change in the shareholding of certain promoter group entities on account of Scheme of Amalgamation
Receipt of US FDA Approval of ELEPSIA ™ XR 1000mg and ELEPSIA ™ XR 1500mg

Allotment of 6060606 equity shares on conversion of warrants
Achievement of milestone - commercialisation of XELPROS ™
Shareholding Pattern - 11th January 2019 POST
Notice of Board Meeting on 4th February 2019
Receipt of Demand Order from the Office of Commissioner of GST & Central Excise
Return of Product Rights by partner for ELEPSIA ™ XR 1000/1500mg
Mandatory Dematerialization for Transfer of Securities

Quarterly Announcements & Disclosures

Details of Independent Directors familiarisation Program - 2016-17
Notice of Board Meeting on 5th May 2017
Outcome of Board Meeting held on 5th May 2017
Notice of EGM - 2nd June 2017
Notice for the 12th Annual General Meeting
Update on Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg) NDA

Allotment of 151,51,515 warrants by the Company
Notice of Board Meeting on 5th August 2017
Annulment of Forfeiture 5th August 2017

Notice of Board Meeting on 27th October 2017
Allotment of Equity Shares - 15th December 2017

Notice of Board Meeting 29th January 2018

Quarterly Announcements & Disclosures

Notice for 11th Annual General Meeting 2015-16

Notice - Completion of dispatch & remote e-voting at 11th AGM
Notice of Board Meeting on 29th July 2016
Press Release - Update on NCE and NDDS Programs
Proceedings of the 11th Annual General Meeting held on 29th July 2016
Voting Results of 11th Annual General Meeting
Postal Ballot Notice and Form - August 2016
News Paper Notice - Postal Ballot 2016
Results of Postal Ballot 2016

Notice of Board Meeting on 28th October 2016
Update of XELPROS
Committee's of the Board

Notice of Board Meeting on 27th January 2017
Authorised KMP - Revised list January 2017
Receipt of IT Demand Notice
Indirect acquisition of controlling stake in the Company by Shanghvi Finance Pvt. Ltd.

Quarterly Announcements & Disclosures

Quarterly Corporate Governance Report for the quarter ended 31st March 2015
Notice of Annual General Meeting FY 2014-2015

Corporate Governance Report for the quarter ended 30th June 2015
Proceedings & outcome of 10th Annual General Meeting

Clarification on incorrect details regarding the Company in certain news articles
Quarterly Corporate Governance Report for the quarter ended 30th September 2015
Authorised KMP

Notice of Board Meeting 3rd February 2016

Quarterly Announcements & Disclosures

Notice of Board Meeting for Consideration of Audited financial results for the year ended 31-03-2014
Notice of Ninth Annual General Meeting for 2013-14 on 31st July 2014

Notice of Board Meeting for Consideration of Un-audited financial results for the Quarter ended 30-06-2014

Notice of Board Meeting for Consideration of Un-audited financial results for the Quarter ended 31-12-2014